Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash & Equivalents (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Cash & Equivalents data on record, last reported at $176.4 million in Q3 2022.

  • For Q3 2022, Cash & Equivalents fell 78.99% year-over-year to $176.4 million; the TTM value through Sep 2022 reached $176.4 million, down 78.99%, while the annual FY2021 figure was $764.4 million, 10.09% down from the prior year.
  • Cash & Equivalents reached $176.4 million in Q3 2022 per AVIR's latest filing, down from $684.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $850.1 million in Q4 2020 and bottomed at $17.1 million in Q1 2020.
  • Average Cash & Equivalents over 3 years is $537.2 million, with a median of $705.5 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 4762.37% in 2021, then tumbled 78.99% in 2022.
  • A 3-year view of Cash & Equivalents shows it stood at $850.1 million in 2020, then dropped by 10.09% to $764.4 million in 2021, then tumbled by 76.92% to $176.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $176.4 million in Q3 2022, $684.5 million in Q2 2022, and $705.5 million in Q1 2022.